30 October 2024
VENTURE LIFE GROUP
PLC
("Venture
Life", "VLG" or the "Group")
Director/PDMR
Shareholding
Venture Life (AIM: VLG), a leader in
developing, manufacturing and commercialising products for the
international self-care market, announces that Mark Adams,
Non-Executive Director, has today purchased 116,496 ordinary shares
of 0.3p each in the Company ("Ordinary Shares") at a volume
weighted average price of 42.79 pence per Ordinary
Share.
Following this purchase, Mr Adams
beneficially holds 175,000 Ordinary Shares representing
approximately 0.14 per cent. of the Company's issued share
capital.
For
further information, please contact:
|
Venture Life Group PLC
|
+44 (0) 1344 578004
|
|
Jerry Randall, Chief Executive
Officer
Daniel Wells, Chief Financial
Officer
|
|
|
Cavendish Capital Markets Limited (Nomad and
Broker)
|
+44 (0) 20 7397 8900
|
|
Michael Johnson (Sales)
Stephen Keys / Camilla Hume
(Corporate Finance)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
About Venture Life (www.venture-life.com)
Venture Life is an international
consumer self-care company focused on developing, manufacturing and
commercialising products for the global self-care market. With
operations in the UK, Italy, The Netherlands and Sweden, the
Group's product portfolio includes some key products such as the
UltraDEX and Dentyl oral care product ranges, the Balance Activ
range in the area of women's intimate healthcare, the Lift and
Glucogel product ranges for hypoglycaemia, Gelclair and Pomi-T for
oncology support, Earol for ear wax removal, products for fungal
infections and proctology, and dermo-cosmetics for addressing the
signs of ageing. Its products are sold in over 90 countries
worldwide.
The products, which are typically
recommended by pharmacists or healthcare practitioners, are
available primarily through pharmacies and grocery multiples. In
the UK and The Netherlands these are supplied direct by the Company
to retailers, elsewhere they are supplied by the Group's
international distribution partners.
Through its two Development &
Manufacturing operations in Italy and Sweden, the Group also
provides development and manufacturing services to companies in the
medical devices and cosmetic sectors.
The
Company makes the following disclosures in accordance with article
19(3) of the Market Abuse Regulation:
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Mark Adams
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Non-Executive Director
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Venture Life Group plc
|
|
b)
|
LEI
|
213800S8CZUPLAB2KC70
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Ordinary Shares of 0.3p each in
Venture Life Group plc
GB00BFPM8908
|
|
b)
|
Nature of the transaction
|
Purchase of ordinary
shares
|
|
c)
|
Price(s) and volume(s)
|
|
Price
|
Volume
|
|
42.8056p
|
58,403
|
|
42.85p
|
23,337
|
|
42.48p
|
14,756
|
|
43.0p
|
5,000
|
|
42.9p
|
5,000
|
|
42.9p
|
5,000
|
|
42.9p
|
5,000
|
|
|
|
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
See above
|
|
e)
|
Date of the transaction
|
30 October 2024
|
|
f)
|
Place of the transaction
|
London Stock Exchange
|
